You are here: Industry Insights > Allergan

News List

Allergan could sell women's health for $6B, if it would only agree to split: analyst fiercepharma
November 21, 2017
RBC Capital Markets analyst Randall Stanicky sees lots of reasons Allergan should pursue a breakup. A women’s health sale that could bring in billions is just one of them.
Allergan Receives FDA Approval for Use of VRAYLAR in Schizophrenia Treatment americanpharmaceuticacreview
November 14, 2017
Allergan announced the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for the maintenance treatment of adults with schizophrenia.
Did Allergan lose its $2.1B Kythera bet, or can chin-fat drug Kybella make its mark? fiercepharma
November 08, 2017
More than two years ago, when Allergan inked a $2.1 billion pact for Kythera, Bernstein analyst Ronny Gal wrote to clients that Allergan “obviously” has “much higher expectations than we do” for chin-fat drug Kybella.
Where could Allergan’s cost cuts fall? DTC spending, for starters fiercepharma
November 03, 2017
Allergan’s investment level over the past year and a half or so has been “fairly high,” thanks to a dozen new products or indications.
Chutes & Ladders—Allergan’s finance overseer to retire fiercebiotech
September 30, 2017
Please send the good word—or the bad—from your shop to Eric Sagonowsky (email) or Angus Liu (email) and we will feature it here at the end of each week.
Allergan receives FDA’s RTF letter for Vraylar sNDA to treat schizophrenia pharmaceufical-technology
September 27, 2017
Schizophrenia is a chronic and disabling disorder that leads to positive symptoms, including hallucinations, delusions and thought disorders, and negative symptoms, such as loss of motivation and social withdrawal.
Allergan embarks on $2 billion share repurchase pharmatimes
September 27, 2017
Allergan is to embark on a new $2 billion share repurchase programme – soon after it completed a separate buyback of $15 billion in its own shares.
Allergan Receives Refusal to File Letter from FDA for Vraylar americanpharmaceuticacreview
September 26, 2017
Upon its preliminary review, FDA determined that the sNDA for treatment of negative symptoms was not sufficiently complete to permit a substantive review.
Allergan posts disappointing data in NASH pharmafile
September 26, 2017
It was only last year that Allergan decided to cough up $1.7 billion to acquire Tobira Therapeutics, with the main driver being its lead candidate for NASH, cenicriviroc (CVC).
Amgen and Allergan’s anti-cancer biosimilar Mvasi receives FDA approval pharmaceufical-technology
September 19, 2017
The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) for the treatment of five types of cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page